Clinical Trials Logo

Hepatitis B clinical trials

View clinical trials related to Hepatitis B.

Filter by:

NCT ID: NCT04629976 Completed - Chronic Hepatitis B Clinical Trials

Activity of NCO-48 Fumarate in Treatment-Naive Adults With Chronic Hepatitis B

Start date: January 12, 2021
Phase: Phase 1
Study type: Interventional

This is an open-label study evaluating multiple doses of NCO-48 Fumarate versus tenofovir alafenamide (TAF).

NCT ID: NCT04585789 Completed - Hepatitis B Clinical Trials

A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection

INSIGHT
Start date: March 11, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess changes in intrahepatic hepatitis B surface antigen (HBsAg) between baseline and on-treatment liver biopsy in response to JNJ-3989-based combination treatment.

NCT ID: NCT04551261 Completed - Chronic Hepatitis B Clinical Trials

GLS4/RTV and TAF Drug-drug Interaction

Start date: January 10, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the drug-drug-interaction (DDI), pharmacokinetics (PK) and tolerability of GLS4/RTV combined with TAF in healthy subjects.

NCT ID: NCT04544956 Completed - Hepatitis B Clinical Trials

A Mechanistic Study of GSK3228836 With Fine Needle Aspiration (FNA) in Participants With Chronic Hepatitis B

B-Fine
Start date: October 6, 2020
Phase: Phase 2
Study type: Interventional

Hepatitis B virus (HBV) infection, especially chronic, is a significant worldwide medical problem. This is an exploratory study of the therapeutic mechanism of GSK3228836 in participants with chronic hepatitis B (CHB) on stable nucleos(t)ide therapy (which is the first line therapy for CHB). This study is a Phase IIa, multi-center open label exploratory study of the therapeutic mechanism of GSK3228836 in participants with hepatitis B virus e-antigen (HBeAg)-negative CHB on stable nucleos(t)ide therapy using repeat fine needle aspirations of the liver for intrahepatic immunophenotyping. It will investigate the virologic and immunologic correlates of hepatitis B virus surface antigen (HBsAg) loss observed in participants when treated for 12 weeks with 300 milligrams (mg) GSK3228836. Repeat fine needle aspirates of the liver will be performed to enable analysis of liver-resident immune cells to investigate any immunomodulatory properties of GSK3228836 and to study the biology of underlying treatment-associated liver flares. The study will consist of a screening, treatment, and post-treatment follow-up phase. Approximately 20 participants will be enrolled in the study.

NCT ID: NCT04539652 Completed - Chronic Hepatitis B Clinical Trials

Clinical Trial to Evaluate the Efficacy and Safety of TenofoBell® Tablet in Chronic Hepatitis B Patients

Start date: September 20, 2018
Phase: Phase 4
Study type: Interventional

This study was designed to evaluate the rate of subjects with HBV DNA less than 20 IU/mL after taking TenofoBell® tablet for 48 weeks

NCT ID: NCT04531098 Completed - Hepatitis B Clinical Trials

A Bridging Study: Comparing Two Lots of Sci-B-Vacâ„¢ and Engerix-B in Healthy Adults

Start date: March 2, 2006
Phase: Phase 3
Study type: Interventional

This was a single-blind, 3-arm, comparative, controlled, randomized, study conducted at one site in Vietnam whose primary objective was to demonstrate clinical equivalence of the two production lots of Sci-B-Vac vaccine produced at two different facilities (OLD facility (Lot A) and NEW facility (Lot B) with respect to anti-hepatitis B-Surface (HBs) response. Secondary efficacy analysis was performed to demonstrate non-inferiority of seroprotection of each lot of Sci-B-Vac vaccine when compared to Engerix-B vaccine

NCT ID: NCT04507269 Completed - Clinical trials for Hepatitis B, Chronic

Study of VIR-2218 in Patients With Chronic Hepatitis B in Mainland China

Start date: August 18, 2020
Phase: Phase 2
Study type: Interventional

This study is to evaluate the safety, pharmacokinetics characteristics, and antiviral activities of multiple doses of VIR-2218 in adults with chronic HBV infection in mainland China.

NCT ID: NCT04503993 Completed - Hepatitis B Clinical Trials

Healthy Planet Hepatitis B

Start date: February 25, 2020
Phase: N/A
Study type: Interventional

This quality improvement project utilizes Epic Health Planet to increase screening for chronic hepatitis B through the creation of registries and ordering of hepatitis B laboratory panels.

NCT ID: NCT04490499 Completed - Hepatitis B Clinical Trials

A Hepatitis B Vaccine Challenge Study After Previous Vaxelis® Vaccination (V419-013)

Start date: September 2, 2020
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate the durability of protection against hepatitis B virus (HBV) infection approximately 8-9 years after vaccination with Vaxelis®. This is an estimation study, and no formal hypothesis testing was performed.

NCT ID: NCT04470388 Completed - Clinical trials for Chronic HBV Infection

A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Treatment

Start date: September 9, 2020
Phase: Phase 1
Study type: Interventional

This is a randomized, double-blind, placebo-controlled study in viremic chronic hepatitis B subjects, assessing the safety, tolerability, pharmacokinetics and antiviral activity of 28 Days treatment with EDP-514.